Searching On:

Disease:

Gene:

ALK

View:
Expand Collapse No disease selected  - General Description
Mass General Hospital Cancer Center treats patients with many cancer types. To learn more about the different cancer types that can be treated at the Cancer Center, please visit the Cancer Center website at the following page: http://www.massgeneral.org/cancer/services/
Expand Collapse ALK  - General Description The ALK gene (ALK stands for Anaplastic Lymphoma Kinase) encodes a protein that is located on the cell surface and belongs to a family of receptor tyrosine kinases (RTKs). RTKs are the first link in a chain that sends signals from the outside of a cell to the signal cascades inside the cell that control different cellular processes, such as cell growth, cell division and cell differentiation. ALK is believed to play a role in brain development and helps to regulate the proliferation of nerve cells during early stages of development. In several types of cancer, the ALK gene has been found to be genetically altered, and these alterations result in abnormal ALK proteins that cannot be normally regulated by the cell. Many types of genetic alterations in the ALK gene have been found in different cancers. Some cancers contain ALK genes that have genetic mutations, or changes in the nucleotide sequence in the ALK gene. Other types of cancers have been found to have amplified ALK, meaning that many copies of the ALK gene have been added to the DNA. This leads to a higher level of the ALK protein in tumor cells, overwhelming the cells normal ability to regulate the ALK protein. Another type of genetic alteration in the ALK gene that is found in cancer is called gene fusions or gene rearrangements. This is the result of an event where a portion of the ALK gene breaks away from its normal location on the DNA, and inserts itself into a different gene in another location. The protein that results from this event is a fusion protein-part ALK, and part of another protein. The gene-fusions found in cancer are activated, and like the mutations and amplifications described above, send continual signals to the cell to grow and divide, resulting in cancer. Source: Genetics Home ReferenceALK is a gene that provides the code for making a protein called anaplastic lymphoma kinase. This protein belongs to a family of proteins on the cell surface known as receptor tyrosine kinases (RTKs). RTKs are the first link in a chain that sends signals from the outside of a cell to the parts inside the cell that control different cellular processes, such as cell growth, cell division and cell differentiation. Anaplastic lymphoma kinase is believed to play a key role in brain development and helps regulate the proliferation of nerve cells during early stages of development. In cancer, either due to mutation or rearrangements in the ALK gene, its activity is continuously switched on, which in turn drives the cancer process. At least 16 mutations in the ALK gene have been found in some patients with neuroblastoma, a cancer that develops in the immature nerve cells (neuroblasts) during childhood. In most cases, each mutation alters the structure of the ALK protein in different ways. These mutations result in the signaling pathway being switched on, increasing the proliferation of immature nerve cells and leading to neuroblastoma. Some of these mutations are inherited and some are called somatic because they are acquired during the course of a person's life and are found only in cells that become cancerous (not inherited from a parent). In some people with neuroblastoma, extra copies (gene amplification) of ALK cause too much protein to be made. Rearrangements in the ALK gene also serve as an important driver of tumor growth. These rearrangements result in the production of a recombinant protein that is comprised of the front end of one protein fused together with the tyrosine kinase domain of ALK. The fusion partner can be any one of a number of genes, depending on the malignancy. For instance, in approximately 70 to 80% of ALK-positive anaplastic large cell lymphomas (ALCL), ALK is paired with the Nucleophosmin (NPM) gene. In lung cancer, ALK's translocation partner is primarily the EML4 gene. ALK rearrangements have also been described in other tumors including inflammatory myofibroblastic tumors, neural tumors, rhabdomyosarcomas and in some subtypes of breast cancer. Another type of rearrangement, an inversion, is found in a few people with non-small cell lung cancer (NSCLC), the most common type of lung cancer. Source: Genetics Home Reference
CLICK IMAGE FOR MORE INFORMATION
The ALK gene (ALK stands for Anaplastic Lymphoma Kinase) encodes a protein that is located on the cell surface and belongs to a family of receptor tyrosine kinases (RTKs). RTKs are the first link in a chain that sends signals from the outside of a cell to the signal cascades inside the cell that control different cellular processes, such as cell growth, cell division and cell differentiation.

ALK is believed to play a role in brain development and helps to regulate the proliferation of nerve cells during early stages of development. In several types of cancer, the ALK gene has been found to be genetically altered, and these alterations result in abnormal ALK proteins that cannot be normally regulated by the cell.

Many types of genetic alterations in the ALK gene have been found in different cancers. Some cancers contain ALK genes that have genetic mutations, or changes in the nucleotide sequence in the ALK gene. Other types of cancers have been found to have amplified ALK, meaning that many copies of the ALK gene have been added to the DNA. This leads to a higher level of the ALK protein in tumor cells, overwhelming the cells normal ability to regulate the ALK protein. Another type of genetic alteration in the ALK gene that is found in cancer is called gene fusions or gene rearrangements. This is the result of an event where a portion of the ALK gene breaks away from its normal location on the DNA, and inserts itself into a different gene in another location. The protein that results from this event is a fusion protein-part ALK, and part of another protein. The gene-fusions found in cancer are activated, and like the mutations and amplifications described above, send continual signals to the cell to grow and divide, resulting in cancer.

Source: Genetics Home Reference
ALK is a gene that provides the code for making a protein called anaplastic lymphoma kinase. This protein belongs to a family of proteins on the cell surface known as receptor tyrosine kinases (RTKs). RTKs are the first link in a chain that sends signals from the outside of a cell to the parts inside the cell that control different cellular processes, such as cell growth, cell division and cell differentiation. Anaplastic lymphoma kinase is believed to play a key role in brain development and helps regulate the proliferation of nerve cells during early stages of development. In cancer, either due to mutation or rearrangements in the ALK gene, its activity is continuously switched on, which in turn drives the cancer process.

At least 16 mutations in the ALK gene have been found in some patients with neuroblastoma, a cancer that develops in the immature nerve cells (neuroblasts) during childhood. In most cases, each mutation alters the structure of the ALK protein in different ways. These mutations result in the signaling pathway being switched on, increasing the proliferation of immature nerve cells and leading to neuroblastoma. Some of these mutations are inherited and some are called somatic because they are acquired during the course of a person's life and are found only in cells that become cancerous (not inherited from a parent). In some people with neuroblastoma, extra copies (gene amplification) of ALK cause too much protein to be made.

Rearrangements in the ALK gene also serve as an important driver of tumor growth. These rearrangements result in the production of a recombinant protein that is comprised of the front end of one protein fused together with the tyrosine kinase domain of ALK. The fusion partner can be any one of a number of genes, depending on the malignancy. For instance, in approximately 70 to 80% of ALK-positive anaplastic large cell lymphomas (ALCL), ALK is paired with the Nucleophosmin (NPM) gene. In lung cancer, ALK's translocation partner is primarily the EML4 gene. ALK rearrangements have also been described in other tumors including inflammatory myofibroblastic tumors, neural tumors, rhabdomyosarcomas and in some subtypes of breast cancer. Another type of rearrangement, an inversion, is found in a few people with non-small cell lung cancer (NSCLC), the most common type of lung cancer.

Source: Genetics Home Reference
Expand Collapse No mutation selected
The mutation of a gene provides clinicians with a very detailed look at your cancer. Knowing this information could change the course of your care. To learn how you can find out more about genetic testing please visit http://www.massgeneral.org/cancer/news/faq.aspx or contact the Cancer Center.

Share with your Physican

Print information for your Physician.

Print information

Your Matched Clinical Trials

Trial Matches: (G) - Gene
Trial Status: Showing Results: 1-10 of 13 Per Page:
12Next »
Protocol # Title Location Status Match
NCT00585195 A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer MGH Open G
NCT02193282 Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) MGH Open G
NCT02201992 Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) MGH Open G
NCT02393625 Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer MGH Open G
NCT02521051 Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer MGH Open G
NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) MGH Open G
NCT02584634 Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) MGH Open G
NCT02817633 A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors MGH Open G
NCT02927340 A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions MGH Open G
NCT03052608 A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC MGH Open G
Trial Status: Showing Results: 1-10 of 13 Per Page:
12Next »

Share with your Physican

Print information for your Physician.

Print information